Published in final edited form as:

Biochem Pharmacol. 2007 June 15; 73(12): 1927–1938.

An Increase of Cytochrome C Oxidase Mediated Disruption of Gemcitabine Incorporation into DNA in a Resistant KB Clone

Xiyong Liu, Bingsen Zhou, Shu Mi, Lijun Xue, Jennifer Shih, Janice Lee, Jennifer Chau, Frank Un, and Yun Yen[#]

Department of Clinical & Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010

Abstract

Mechanistic aberrations leading to Gemcitabine (2', 2'-dFdCyd, 2, 2-difluorodeoxycytidine, Gem) resistance may include alteration in its transport, metabolism and incorporation into DNA. To explore the mechanism of Gem resistance, the restriction fragment differential display PCR (RFDD-PCR) was employed to compare the mRNA expression patterns of KBGem (Gem resistant), KBHURs (Hydroxyurea resistant), and KBwt (parental KB cell). Nine gene fragments were overexpressed specifically in the KBGem clone. Sequencing and BLAST results showed that three fragments represent Cytochrome C Oxidase (CCOX, respiration complex IV) subunit III (CCOX3). The cDNA microarray confirmed that the mRNAs of CCOX and ATP synthase subunits were upregulated in KBGem as compared to KBwt and KBHURs. The increase in CCOX1 protein and activity led to the increase of free ATP concentration, which is consistent with the gene expression profile of KBGem. Furthermore, the sensitivity to Gem could be reversed by sodium azide, a CCOX inhibitor. Following the treatment of sodium azide, the cellular accumulation of [³H]-Gem increased in a dose (of azide)-dependent manner, which is associated with increase of [³H]-Gem incorporation into DNA in KBGem. In summary, an increase of CCOX activity and free ATP level may reduce the transport, metabolism and DNA incorporation of Gem, resulting in Gem resistance.

Keywords

gemcitabine; drug resistance; cytochrome C oxidase; ribonucleotide reductase; ATP

1. Introduction

Gemcitabine (2', 2'-dFdCyd, 2, 2-difluorodeoxycytidine, Gem), a deoxycytidine analogue, is widely used in the treatment of hematological malignancies and solid tumors [1]. Gem is sequentially phosphorylated by deoxycytidine kinase (dCK), dCMP kinase (dCMPK), and nucleoside diphosphate kinase (NDPK), which is then further metabolized to form dFdCDP and dFdCTP [2,3]. As a competitor of dCTP, dFdCTP is incorporated into DNA during replication causing chain termination [4,5]. Drug resistance is the major limiting factor for Gem based therapy. The resistance to Gem can be caused by a number of factors affecting its transport, metabolism and incorporation into DNA [6]. These factors include a deficiency in the equilibrative/concentrative nucleoside transporter protein [7–10], an increased

[#]Correspondence: Yun Yen, M.D., Ph.D., F.A.C.P., Department of Clinical & Molecular Pharmacology, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010-3000, Phone: (626) 359-8111 ext. 62867, Fax: (626) 301-8233, E-mail: yyen@coh.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

nucleotidase that catalyze the conversion of nucleotide back to nucleoside [11], a loss of dCK expression [12,13], and an increase in hRR activity [14,15]. It has been suggested that the increase in hRR activity will lead to expand the dCTP pool, which may then competitively inhibit the incorporation of dFdCTP into DNA during replication [15]. However, the mechanism cannot completely explain how the increase in hRRM2 leads to Gem resistance. A 10-fold increase in hRRM2, resulting in a 2-fold increase of the dCTP pool increase, cannot fully explain the 100-fold increase in resistance observed in a Gem resistant clone (KBGem). It implies that as yet unidentified factor may act synergistically with overexpressed hRRM2 to cause Gem resistance.

Cytochrome C Oxidase (CCOX, complex IV, EC:1.9.3.1.), the terminal enzyme in the respiratory chain, is located in the inner membrane of mitochondria [16]. It reduces oxygen to water and pumps protons across the inner mitochondrial membrane. This proton gradient is used by ATP synthase to generate ATP [17]. CCOX contains 13 subunits per monomer. Subunit I, II and III are responsible for the enzyme's catalytic activity, and are encoded by the mitochondrial genome [18]. Nuclear genes encode the other 10 subunits of CCOX [19]. Under the physiological condition, CCOX has been shown to be the rate-limiting enzyme of oxidation [16]. The activity of CCOX is allosterically regulated by the ATP/ADP ratio [17,20]. Azide and cyanide exhibit specific inhibitory effects on the mitochondrial CCOX [21]. Alteration of CCOX subunits has been reported in adriamycin, doxorubicin and cisplatin resistant clones [22,23]. Yet, how CCOX affects resistance to nucleoside analogues is not known.

In this report, we show that CCOX subunit is overexpressed in a Gem resistant clone (KBGem) overexpressing hRRM2. Microarray results further show that many genes of the respiration complex IV (Cytochrome C Oxidase) and complex V (ATP synthase) families were upregulated in KBGem. The increase in CCOX activity and free ATP level was also confirmed in KBGem. Furthermore, sodium azide, a CCOX inhibitor, could revert the Gem resistance in KBGem. Thus, increasing the CCOX expression and activity may alter Gem's efflux and metabolism, contributing to Gem resistance.

2. Material and Methods

2.1. Cell Culture and Gem resistant clones' selection

The human oropharyngeal epidermal carcinoma cell line KB was purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown in RPMI 1640 medium supplemented with 10 % fetal bovine serum and 1 % Penicillin-Streptomycin. The selection of Gem resistant clones was based on KB cell step-wise exposure to increased concentrations of Gem [15]. The Gem resistant clones were selected and maintained in the presence of 8 μ M Gem.

2.2. Western Blots

Each cell lysate (40 μ g) was separated and transferred to a PVDF membrane. The transferred PVDF membranes were incubated in blocking buffer (1 % I-blockTM reagent and 0.1 % Tween-20) with the primary antibody (1:200 dilution) for 45 minutes at room temperature, washed with blocking buffer, and then incubated with 1 % I-blockTM blocking buffer with alkaline phosphatase conjugated secondary antibody (1:2000 dilution) for 30–60 minutes. This was followed by sequential washes with 0.5 % I-blockTM buffer and assay buffer (200 mM Tris-HCl, 10 mM MgCl₂). Then a thin layer of CSPD Ready-to-Use substrate solution (Applied Biosystems, Foster City, CA) was transferred over the membrane. After a 5-minute incubation, the membrane was exposed to X-ray film for 3 minutes.

2.3. Restriction Fragment Differential Display PCR (RFDD-PCR)

The analysis RFDD-PCR was carried out as described in detail in the protocol from the display PROFILE kit (Qbiogene, Irvine, CA). Briefly, the total mRNA was extracted from KBwt, KBGem and KBHURs by using Oligotex mRNA Midi Kit (QIAGEN, Valencia, CA). Total mRNA was reverse-transcribed using a randomized octamer primer to synthesize cDNA. Then, 10 μ l cDNA was digested with TaqI endonuclease at 65 °C for 2 hours. The RFDD-PCR template was completed by ligating the digest to adaptor mixture containing an extension protection group at 37 °C for 3 hours using T4 DNA ligase.

The template was PCR amplified using a 0-extension primer complementary to the EP adaptor in combination with a 3-extension primer recognizing the standard adaptor and the three nucleotides adjacent to the TaqI site. The 0-extension primer was fluorescently labeled with Cy5. All PCR reactions were carried out in a 20 μ l volume using 0.2 μ l template and standard concentration of dNTPs and primers. For each template, 32 PCR reactions using the Cy5-labelled 0-extension primer in combination with the 32 different 3-extension primers (NNA/G or NNC/T) were performed. The PCR products were separated on a standard 6 % polyacrylamide sequencing gel. Bands corresponding to those indicated by the fluorescence-based analysis to be differentially expressed were identified on the autoradiogram. The dried gel was lined up with markings on the film and the fragments were excised from the gel. The gene fragments were re-amplified using the same PCR conditions and primers as in the initial PCR reaction. The PCR re-amplified products were sequenced by City of Hope co-facility.

2.4. Cytochrome C oxidase activity assay

The Cytochrome C Oxidase assay kit (Product Code: CYTOC-OX1) was purchased from SIGMA (St Louis, MO). Briefly, assays contained 400 μ g fresh cell lysates and were performed at room temperature in 1.1 ml reaction volumes. The assay involved the addition of 0.01 mM ferrocytochrome c in assay buffer (10 mM Tris-HCl pH 7.0, 120 mM KCl). The activity was calculated from the rate of decrease in absorbance of ferrocytochrome c at 550 nm ($\Delta\epsilon^{\text{mM}}=21.84$) and results were normalized by an internal control provided by the kit.

2.5. Microarray analyses

The mRNA isolation, cRNA preparation, microarray hybridization and data analysis have been described in our previous publication [24,25]. The HG-U95Av2 microarray set from Affymetrix (Santa Clara, CA) was employed to analyze the gene mRNA expression. The analyses were performed at the Microarray Core Facility, Children's Hospital Los Angeles. The data was analyzed using Affymetrix Microarray Software Suite (v.4.0) and GeneSpring™ (v7.0) software (Silicon Genetics, Foster City, CA). The quality of hybridization was evaluated with internal control spots. Each chip was normalized with the standard protocol of the core facility. Spots representing housekeeping genes were further used to normalize the entire slide so that all slides could be compared directly. This microarray data has been deposited to Geo (<http://www.ncbi.nih.gov/geo/>). The access number of KBwt, KBGem and KBHURs are GSM69543, GSM69658 and GSM69660, respectively.

2.6. ATP concentration detection assay

The concentration of ATP was determined using the ENLITEN® ATP Assay system (Promega, Madison WI). About 1×10^6 cells were harvested and counted, and then suspended in 200 μ l of 10 % TCA solution on ice for 20 minutes. After centrifuging for 10 minutes, the supernatant was collected and diluted 1:100 in 50 mM Tris-HCl buffer (pH 8.0), and stored at -80 °C for detection. The reaction included 100 μ l of rL/L reagent buffer and 20 μ l of the diluted sample. Fresh standard ATP samples were prepared to measure the concentration of samples.

2.7. [³H] labeled Gem and dCy cell uptake and DNA incorporation assay

About 1×10^6 cells were evenly seeded on 100 mm² cell culture dishes. To inhibit CCOX activity, the cells were incubated with 0, 7.5, 15, 30, 60 and 120 μ M of sodium azide (Sigma) for 3 hours, and then incubated with [³H] labeled Gem (Moravek Biochemicals, Brea, CA) (3.5 μ Ci/ml, 0.25 nmol/ml) or [³H] deoxycytidine (dCy, Moravek Biochemicals, Brea, CA) (3.5 μ Ci/ml, 0.25 nmol/ml) for another 3 hours. Cells were washed twice and harvested using 0.5 % trypsin. The incubation medium was collected and measured with a scintillation counter as a control. DNA was extracted from 8×10^5 cells using QIAamp® DNA Mini extraction kit (QIAGEN, Valencia, CA). The DNA concentrations were measured and detected by 280 nm and 260 nm wavelengths. The cell uptake and DNA incorporation of [³H]-Gem/dCy were measured with one-fifth cell pellets (about 2×10^5 cells) and 50 μ g of DNA samples by liquid scintillation counter respectively. The [³H]-Gem/dCy DNA incorporation was adjusted by DNA concentration.

2.8. Statistics

Data was collected using an MS-Excel spreadsheet. Data was analyzed using the JMP Statistical Discovery Software version 6.0 (SAS Institute, Cary, NC). Comparisons for continuous data were performed using t-tests for independent means or one-way analyses of variance. Error-bars are instead of Standard deviation. Statistical significance was set at $p < 0.05$.

3. Results

3.1. Characterization of the Gem resistant cell line KBGem

To explore the mechanisms of Gem resistance, we isolated a Gem resistant clone (KBGem) via step-wise selection. KBGem was maintained in 8 μ M of Gem (IC₅₀ of parental KB cell is 0.3 μ M) [15]. The hydroxyurea drug resistant clone KBHURs and the parental KB cells (KBwt) were used as controls. KBHURs was also selected via step-wise selection. Previously, it was shown that KBHURs overexpress hRRM2 at mRNA and protein levels, and exhibits cross-resistance to Gem phenotype [15]. The characteristics of KBwt, KBGem and KBHURs clones are summarized in Table 1. Using an upgraded version of phosphorimage scanner and a quantitative software (ImageQuant 5.2), a greater increase of hRRM2 was detected in KBGem and KBHURs than we previously reported [15]. KBGem and KBHURs express 29.3 and 32.0 fold higher level of hRRM2 mRNA with 9.0 and 10.0 fold increase in hRRM2 protein, respectively. It led to approximately 2.3 and 6.7 fold increase in RR activity, which, in turn, caused 2 and 14 fold expansion of dCTP pool in KBGem and KBHURs, respectively. These results indicated that both KBGem and KBHURs overexpressed hRRM2 in similar range, but discrepancy of gem resistance could be based on different molecular mechanisms.

3.2. Identification of highly-expressed gene fragments in KBGem

To investigate as yet unidentified factors contributing to Gem resistance in KBGem, RFDD-PCR was employed to compare transcript patterns among the above clones. The Cy5-labelled RFDD-PCR products were separated through a polyacrylamide gel and the results pattern was analyzed with ImageQuant 5.2 software. The difference in the expression level was quantitated by comparing peak areas (Figure 1A & 1B). Only the fragments with at least a five-fold increase in expression were considered for the analysis. In total, nine gene fragments were identified with a higher expression in KBGem compared to KBwt and KBHURs. Those nine fragments were re-harvested and re-amplified using corresponding primers. The sequences of the fragments were used to identify genes using Genbank's BLAST program. As shown in Table 2, nucleotide–nucleotide BLAST (blastn) alignments indicated that five of the nine fragments (E12G5-5, E33G5, E33G5L, E34G5L, and E51G5) exhibit a high-degree of similarity to

mitochondrion. E32G5, E48G5 and E9G5-10 were identified as poly (A) binding protein, thymosin beta 10, and TNF receptor-associated factor 4 isoform 1, respectively. Searches performed using translated sequence as query against the protein sequence database (blastx) identified three fragments as cytochrome C oxidase subunit III (E12G5-5, E33G5L, E34G5L), and one fragment as NADH dehydrogenase subunit 1. It indicated that an increase of CCOX and other mitochondrial respiration complexes may be related to the Gem resistance phenotype of KBGem.

3.3. Determination genes of the expression profile of respiratory complex subunits using cDNA microarray

cDNA microarray analysis was used to further validate the expression pattern of the genes relating to CCOX function. Signals were normalized with an internal control chip. After normalization, numerous changed genes were detected in KBGem and KBHURs, but most of affected genes appeared to have little relevance to the Gem resistance mechanism (data not show). Because Affymetrix HG-U95Av2 microarray did not include mitochondrial genes, the expression of CCOX subunit I, II and III could not be detected. Here, by filtering the present signal (P) using Genespring software, valid signals of respiration complex subunits are shown (Table 3). The results showed that most of the genes in complex I (NADH Dehydrogenase), complex IV (Cytochrome C Oxidase) and complex V (ATP synthase) were upregulated in KBGem (compared to KB, paired t-test, $p=0.004$). Most of the listed genes did not show difference that is statistically significant between KBHURs and KBwt (paired *t-test*, $p=0.076$). The NADH dehydrogenase subunit 1 that was identified as an upregulated gene via RFDD-PCR increased slightly in KBGem. Nevertheless, the above results indicate that most of the genes of the respiration complexes were increased in KBGem, which may be associated with Gem resistance.

3.4. Increase of CCOX subunits expression and activity in KBGem

To confirm the up-regulation of CCOX in Gem resistant cells, the expression level of CCOX subunits and CCOX activity were determined in KBGem. The Western blot results showed that the CCOX subunit 1 increased 3.6-fold in KBGem, but only 1.7-fold in KBHURs (Figure 2A). The CCOX subunit 2 and 3 levels could not be similarly determined due to the inefficient antibodies. KBGem had a higher CCOX activity than KBwt and KBHURs, but a large variation between samples prevent us from determining statistical significance (Figure 2B). As CCOX represents the terminal enzyme in the respiratory chain providing the proton gradient for ATP synthesis, the ATP concentration was also determined. KBGem exhibited approximately 4-fold increase of ATP concentration in comparing to KBwt and KBHURs (Figure 2C). The above findings confirmed that the increase in CCOX ATP synthase of the respiration complex is associated with Gem resistance phenotype in KBGem.

3.5. Reversal of Gem resistance by using CCOX inhibitor in KBGem

The effect of azide on mitochondrial respiratory enzymes is limited to CCOX [26]. The treatment dose of sodium azide was based on a previous study [27]. Following the treatment with azide at 30 μM , the survivability of KBwt was little affected, but the IC_{50} of KBGem for Gem decreased from 33.2 μM to 15.3 μM (Figure 3A). A similar co-treatment with azide did not significantly impact survivability of KBGem to SAHA (a HDAC inhibitor) and ps341 (a proteasome inhibitor) (data not shown). Above results indicated Azide could enhance sensitivity of Gem, rather than SAHA and ps341, in KBGem clone.

The cytotoxicity of Gem (dFdCyd) occurs, mostly, through its incorporation into DNA as dFdCTP and causing masked chain termination [4,5]. Hence, the effect of azide on the rate of Gem incorporation into DNA was examined. Cells were treated with 0, 7.5, 15, 30, 60 and 120 μM of azide, the incorporation of [^3H] labeled Gem into DNA increased with increase of azide

in KBGem and KBwt (Figure 3B). It indicated sensitization to Gem by azide involves enhancing the rate of Gem incorporation into DNA. Taken together, the resistance to Gem in KBGem can be partially reversed by sodium azide.

3.6. Increase of [³H]-Gem accumulation in KBGem by sodium azide

The uptake assay demonstrated that cellular accumulation of KBwt is almost 10-fold higher than in KBGem, when cells were incubated with 85, 175, 350 or 700 nM of [³H]-Gem (Figure 4A). When pre-treated with 0, 7.5, 15, 30, 60 or 120 μ M of azide, the cellular accumulation of [³H]-Gem increased in a dose (of azide)-dependent manner in KBwt and KBGem (Figure 4B). Based on the covariance analysis, azide has a positive impact on [³H]-Gem accumulation ($p < 0.05$); this effect on KBGem is much more pronounced than that on KBwt. The [³H]-dCy uptake by KBwt is only 1/10th of that in KBGem; and sodium azide did not affect the accumulation of [³H]-dCy in both KBwt and KBGem clones (Figure 4C). Thus, sodium azide effectively enhances the accumulation of Gem, but not dCy, in KBGem.

As shown in Figure 5A, the efflux assay showed that 38–39 % of total uptake [³H]-Gem could be detected in the medium after treated KBwt was freshly cultured with normal medium for 1 hour. KBGem could efflux 60–80 % of total uptake [³H]-Gem in 1 hour. The potential for Gem efflux increased in a dose-dependent manner. After incubating with fresh medium for 24-hour, only 0.25–0.47 % and 0.04–0.13 % of absorbed [³H]-Gem could be detected in KBwt and KBGem cells, respectively. As shown in Figure 5B, under treatment of 7.5, 15, 30, 60 and 120 μ M of azide in KBwt, the efflux of [³H]-Gem (1 hour) was reduced to 44.7 %, 18.1 %, 21.9 %, 15.3 % and 17.1 %, respectively. Covariance analysis indicated that azide reduces efflux of [³H]-Gem significantly ($p < 0.05$). However, the efflux of [³H]-dCy did not change significantly when treated with different doses of azide ($p > 0.05$) (Figure 5C). The above findings suggested that azide decreases [³H]-Gem efflux, which cause increase of [³H]-Gem accumulation.

4. Discussion

Drug resistance limits the application of Gem therapy in clinics treatments [6]. Further understanding of the mechanism underlying Gem resistance may help to enhance the efficacy of nucleoside analogs in cancer chemotherapy. An increase of hRRM2 has been causally linked to Gem resistance by our laboratory and others [15,24,28,29]. Besides hRRM2, the subunit hRRM1 and p53R2 have also been implicated in Gem resistance [14]. In addition, an increase of RR activity may contribute to resistance to fludarabine, a distinct nucleoside analogue, in human T-cells [30]. Gem sensitivity could be enhanced by inhibiting hRRM2 expression using siRNA, antisense RNA, or RR inhibitor [29,31]. However, other investigations showed that RR inhibition can not completely reverse the resistance to Gem. Thus, an increase of hRR only partially accounts for the high-degree of resistance exhibited by several resistant clones.

Alteration of CCOX subunits expression has been observed in doxorubicin and adriamycin multi-drug resistant K562 cells [22,23]. Cells associated with resistance to chemotherapeutic agents and radiation characteristically have a lower mitochondrial membrane potential, smaller proton gradients in the mitochondria, and a higher use of fat etc. [32]. It indicated that modification of nuclear and/or mitochondrial genome(s) may occur following the step-wise selection for drug resistance in cancer cells. Nevertheless, the molecular mechanism of resistance to nucleoside analogues may differ from the resistance to DNA damaging drugs. In this study, four of nine gene fragments overexpressed in KBGem from RFDD-PCR analysis were identified as CCOX subunits. Further cDNA microarray analysis showed the ATP synthase (complex V) subunits are also increased in KBGem. The upregulation of CCOX subunit 1 and activity in KBGem have been confirmed via western blot and enzymatic activity assay, respectively (Figure 2). It led to an increase of free-ATP by almost 4-fold in the KBGem

(Figure 2C). Due to its ability to selectively inhibit CCOX of the electron transport chain, azide has been widely used as an inhibitor to study CCOX and other hemoproteins [21]. Sodium azide could significantly enhance the [³H]-Gem incorporation into DNA and improve Gem sensitivity by reducing Gem efflux in KBGem. The above data indicate that an increase of CCOX may contribute to Gem resistance in KBGem.

Several molecular signaling pathways may regulate how CCOX affects Gem resistance. Increasing CCOX may reduce the accumulation of Gem by modulating influx/efflux nucleoside transporter protein through free ATP. The four different types of transporter process for nucleoside analogues are summarized into: (1) equilibrative uniport, (2) substrate exchange, (3) concentrative Na⁺- or H⁺-dependent uptake, (4) substrate export through primary ATP-dependent active efflux pumps [33]. Nucleoside related transporters mainly include the equilibrative/concentrative nucleoside transporter (ENT/CNT), organic anion transporter (OAT) and organic cation transporter (OCT), peptide transporter (PEPT) and multi-drug resistance protein (MRP). In mammalian cells, at least two subtypes of equilibrative and three distinct Na⁺-dependent concentrative nucleoside transporters are involved in nucleoside transport [34,35]. We found that the [³H]-Gem accumulation in KBGem was only one-tenth of that to KBwt (Figure 4A). After one hour, almost 60–80 % of [³H]-Gem was effluxed in KBGem, which is significantly higher than that in KBwt (Figure 5A). Another group reported that ATP-replete cells accumulated significantly less [³H]-Gem than did ATP-depleted cells, which suggested an efflux mechanism for Gem [36]. Our observation also yielded similar results by using sodium azide, a CCOX inhibitor (Figure 5B). Increasing the ATP concentration might enhance the efflux of Gem by affecting the Na⁺/K⁺ ATP pump channel. The most common ATP dependent efflux pump for a cytotoxicity drug is the multi-drug resistance (MDR) transporter P-glycoprotein (P-gP) [37]. There is no evidence indicating that Gem is a substrate of the MDR system. However, the sensitivity of Gem was increased in a MDR P-gP overexpressing lung cell line [38]. Therefore, how CCOX regulates the Gem influx/efflux transporter still requires further investigation.

CCOX might synergistically interact with hRR and contribute to Gem resistance via increasing free ATP concentration. A recombinant mouse RR model demonstrated that free ATP regulates RR activity by binding to a specificity site (S-site), an adenine-specific site (A site), and a hexamerization site (H-site) of the RR large subunit [39–41]. An increase of free ATP drives RR subunits to form an active (R1)₂(R2)₂ dimer and a (R1)₆(R2)₆ hexamer [41]. Utilizing recombinant human RR subunits, an in vitro enzymatic activity assay showed that the holoenzyme hRRM1/hRRM2 and hRRM1/p53R2 have no activity without free ATP [42]. Several groups have demonstrated that overexpression of hRR subunits, including hRRM2, hRRM1 and p53R2, is associated with Gem resistance [14,15,29]. hRRM2 overexpression and hRR activity upregulation in KBGem was reported in several of our previous publications [15,24,28,31]. Therefore, increasing free ATP concentration may regulate hRR subunits to form excess active RR holoenzyme, which, in turn, causes an expansion in the dCTP pool.

Increase of CCOX activity may alter the Gem metabolic pathway via ATP in KBGem. The phosphorylation of Gem is mediated by dCK, dCMPK and NDPK enzyme. While cytidine is phosphorylated by uridine kinase and cytidylate kinase. This is followed by RR reduction, and phosphorylation by NDPK (Figure 6). We previously showed that dCK does not contribute to Gem resistance in KBGem [15]. Recently, an in vitro activity assay utilizing recombinant proteins demonstrated that free ATP inhibits the activity of dCMPK, but not cytidylate kinase (CK) [43]. When the ATP level increased from 2 mM to 5 mM, the efficiency of dFdCMP phosphorylation was reduced to about 64.7 %. Whereas, ATP enhanced the CMP phosphorylation by mere 4.3 % [43]. It suggested that the increase of CCOX activity results in an increase of ATP may reduce the phosphorylation of dFdMP in KBGem, and interruption of dFdCMP phosphorylation may block the dFdCTP formation. The decrease of dFdCTP and

the expansion of the dCTP pool would prevent dFdCTP incorporation into DNA, which would contribute to Gem resistance in KBGem.

The above findings revealed that upregulation of free ATP level may represent a key molecular in Gem resistance signaling pathway in KBGem. The mechanisms of CCOX involving Gem resistance may occur through the following pathway (Figure 6): (1) Increasing CCOX enhances Gem efflux through increasing of free ATP; (2) reducing the dFdCTP formation through inhibiting dCMP kinase; (3) activating hRR activity and cytidylate kinase to provide excess dCTP to compete dFdCTP incorporation into DNA.

Acknowledgements

This study was financed by National Institute of Health (NIH) RO-1 grant (CA 72767).

References

- Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. *Lancet Oncol* 2002;3:415–24. [PubMed: 12142171]
- Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. *Semin Oncol* 1995;22:11–8. [PubMed: 7481839]
- Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potential. *Semin Oncol* 1995;22:3–10. [PubMed: 7481842]
- Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. *Cancer Res* 1991;51:6110–7. [PubMed: 1718594]
- Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. *Cancer Res* 1996;56:4453–9. [PubMed: 8813140]
- Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. *Leukemia* 2001;15:875–90. [PubMed: 11417472]
- Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. *Clin Cancer Res* 2002;8:110–6. [PubMed: 11801546]
- Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. *Cancer Sci* 2004;95:753–7. [PubMed: 15471562]
- Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. *Clin Cancer Res* 2003;9:5000–8. [PubMed: 14581375]
- Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. *Cancer Res* 1998;58:4349–57. [PubMed: 9766663]
- Galmarini CM, Jordheim L, Dumontet C. Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies. *Leuk Lymphoma* 2003;44:1105–11. [PubMed: 12916861]
- Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. *BMC Pharmacol* 2004;4:8. [PubMed: 15157282]
- Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermesen M, et al. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. *Cancer Res* 1994;54:4138–43. [PubMed: 8033147]
- Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. *Cancer Res* 2004;64:3761–6. [PubMed: 15172981]
- Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. *Cancer Res* 1999;59:4204–7. [PubMed: 10485455]

16. Richter OM, Ludwig B. Cytochrome c oxidase--structure, function, and physiology of a redox-driven molecular machine. *Rev Physiol Biochem Pharmacol* 2003;147:47–74. [PubMed: 12783267]
17. Ludwig B, Bender E, Arnold S, Huttemann M, Lee I, Kadenbach B. Cytochrome C oxidase and the regulation of oxidative phosphorylation. *Chembiochem* 2001;2:392–403. [PubMed: 11828469]
18. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. *Nature* 1981;290:457–65. [PubMed: 7219534]
19. Capaldi RA. Structure and function of cytochrome c oxidase. *Annu Rev Biochem* 1990;59:569–96. [PubMed: 2165384]
20. Shoji K, Tanigawa M, Hori K, Tomozawa Y, Yamanaka T. The effects of several nucleotides on the molecular state and catalytic activity of *Thiobacillus novellus* cytochrome c oxidase. ATP affects the oxidase uniquely. *Eur J Biochem* 1999;264:960–4. [PubMed: 10491145]
21. Chen YR, Sturgeon BE, Gunther MR, Mason RP. Electron spin resonance investigation of the cyanide and azidyl radical formation by cytochrome c oxidase. *J Biol Chem* 1999;274:24611–6. [PubMed: 10455126]
22. Grandjean F, Bremaud L, Robert J, Ratinaud MH. Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. *Biochem Pharmacol* 2002;63:823–31. [PubMed: 11911833]
23. Denis-Gay M, Petit JM, Mazat JP, Ratinaud MH. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells. *Biochem Pharmacol* 1998;56:451–7. [PubMed: 9763220]
24. Liu X, Zhou B, Xue L, Qiu W, Shih J, Zheng S, et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. *Biochem Pharmacol* 2004;67:1499–511. [PubMed: 15041467]
25. Qiu W, Zhou B, Zou H, Liu X, Chu PG, Lopez R, et al. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. *Am J Pathol* 2004;165:1689–99. [PubMed: 15509538]
26. Leary SC, Hill BC, Lyons CN, Carlson CG, Michaud D, Kraft CS, et al. Chronic treatment with azide in situ leads to an irreversible loss of cytochrome c oxidase activity via holoenzyme dissociation. *J Biol Chem* 2002;277:11321–8. [PubMed: 11796734]
27. Karu TI, Pyatibrat LV, Kalendo GS. Photobiological modulation of cell attachment via cytochrome c oxidase. *Photochem Photobiol Sci* 2004;3:211–6. [PubMed: 14872239]
28. Zhou B, Mo X, Liu X, Qiu W, Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. *Cytogenet Cell Genet* 2001;95:34–42. [PubMed: 11978967]
29. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. *Oncogene* 2004;23:1539–48. [PubMed: 14661056]
30. Mansson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. *Biochem Pharmacol* 2003;65:237–47. [PubMed: 12504799]
31. Zhou B, Mi S, Mo X, Shih J, Tsai J, Hu E, et al. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. *Anticancer Res* 2002;22:1369–77. [PubMed: 12168813]
32. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemio M, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. *Faseb J* 2002;16:1550–7. [PubMed: 12374777]
33. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J, et al. Cell entry and export of nucleoside analogues. *Virus Res* 2005;107:151–64. [PubMed: 15649561]
34. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. *Adv Enzyme Regul* 1993;33:235–52. [PubMed: 8356910]
35. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. *Biochim Biophys Acta* 1996;1286:153–81. [PubMed: 8982282]

36. Hammond JR, Lee S, Ferguson PJ. [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. *J Pharmacol Exp Ther* 1999;288:1185–91. [PubMed: 10027857]
37. Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. *Physiol Rev* 1997;77:545–90. [PubMed: 9114823]
38. Bergman AM, Pinedo HM, Veerman G, Kuiper CM, Peters GJ. Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines. *Adv Exp Med Biol* 1998;431:591–4. [PubMed: 9598134]
39. Kashlan OB, Scott CP, Lear JD, Cooperman BS. A comprehensive model for the allosteric regulation of mammalian ribonucleotide reductase. Functional consequences of ATP- and dATP-induced oligomerization of the large subunit. *Biochemistry* 2002;41:462–74. [PubMed: 11781084]
40. Scott CP, Kashlan OB, Lear JD, Cooperman BS. A quantitative model for allosteric control of purine reduction by murine ribonucleotide reductase. *Biochemistry* 2001;40:1651–61. [PubMed: 11327824]
41. Cooperman BS, Kashlan OB. A comprehensive model for the allosteric regulation of Class Ia ribonucleotide reductases. *Adv Enzyme Regul* 2003;43:167–82. [PubMed: 12791390]
42. Qiu W, Zhou B, Darwish D, Shao J, Yen Y. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. *Biochem Biophys Res Commun* 2006;340:428–34. [PubMed: 16376858]
43. Hsu CH, Liou JY, Dutschman GE, Cheng YC. Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium. *Mol Pharmacol* 2005;67:806–14. [PubMed: 15550676]
44. Zhou BS, Ker R, Ho R, Yu J, Zhao YR, Shih J, et al. Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. *Biochem Pharmacol* 1998;55:1657–65. [PubMed: 9634002]

Abbreviations

Gem	2', 2'-dFdCyd, 2, 2-difluorodeoxycytidine, Gemcitabine
dCK	deoxycytidine kinase
dCMPK	dCMP kinase
NDPK	nucleoside diphosphate kinase
CK	cytidylate kinase
CCOX	cytochrome C oxidase
ENT	equilibrative nucleoside transporter
CNT	concentrative nucleoside transporter
OAT	organic anion transporter
OCT	organic cation transporter

PEPT	peptide transporter
MRP	multi-drug resistance protein
KBGem	gemcitabine drug resistant KB clone
KBHURs	hydroxyurea drug resistant KB clone
KBwt	parental KB cell
hRR	human ribonucleotide reductase
hRRM1	human ribonucleotide reductase large subunit M1
hRRM2	human ribonucleotide reductase small subunit M2
p53R2	p53 dependent human ribonucleotide reductase small subunit R2 (M2B)
dNTP	deoxyribonucleoside triphosphate
NDP	ribonucleoside diphosphate
RFDD-PCR	restriction fragment differential display PCR

Figure 1. Fluorescent RFDD-PCR analysis for KBwt, KBHURs and KBGem

The left panel (A) shows subsequent fluorescent analysis and the identification of the bands for gel excision. The right panel (B) shows identification of the high expression fragments using ImageQuant 5.2 software. The fragment (α) is E12G5-5 overexpressing in KBGem only.

Figure 2. Increase of CCOX1 expression and activity in KBGem clone

A) Western Blot: The mouse antibody against CCOX subunit 1 was employed to determine protein levels in KBwt, KBGem and KBHURs clones. The α -tubulin was a loading control. Error bars are used instead of standard deviation. B) In vitro CCOX activity assay: 100 μ g of cell lysates extracted from each cell clone were used to evaluate the CCOX activity. The activity calculation was performed according to the parameter described in the Materials and Methods section. C) The free ATP was determined using the ENLITEN[®] ATP Assay system. Cell number was employed to normalize the ATP concentration.

A.

B.

[3 H]-Gem DNA incorporation assay

Figure 3. Determining Gem sensitivity and incorporation into DNA under treatment of azide
 A) Cytotoxicity assay: About 5000 cells/100 μ l was seeded to a 96 wells plate. 30 μ M of sodium azide was added to the azide treatment group. After incubating for 72 hours, each well was added 20 μ l of Aqueous One Solution Reagent (Promega, Madison WI) and then incubated for an additional 2 hours. After incubation, each well read the O.D. at 490 nm. Cells' survival curve was normalized by corresponding control. B) DNA incorporation assay: Cells were pre-treated with different dosages of sodium azide, CCOX specific inhibitor, for 3 hours. Following incubation of [3 H] labeled Gem/cytidine (3.5 μ Ci/ml, 0.25 nmol/ml) for another 3 hours, the cells were washed with PBS twice, and then trypsinized and harvested. Genomic DNAs were

extracted and concentration determined. 50 µg of extracted DNA was counted for tritium signal value.

Figure 4. Determining [³H]-Gem accumulation in KBGem under treatment of Azide

A) [³H]-Gem accumulation assay: 2×10^5 cells of KBwt and KBGem were plated onto 12 well plates, and [³H]-Gem was then added at 85, 175, 350 and 700 nM. The cells were harvested after 72 hours, and the whole cells were counted. Each done repeated in triplicate. B) 2×10^5 cells were pre-treated with 0, 7.5, 15, 30, 60 and 120 μM of sodium azide for 3 hours. Following the incubation of [³H] labeled Gem (0.5 μCi/ml, 0.02nmol/ml) for another 3 hours, cells were washed with PBS twice, and then harvested. 1/5 harvested cell pellet was counted using liquid scintillation counter. The DNAs were extracted from the remaining 4/5 of cell pellets. Results were adjusted with DNA concentration, and then normalized with corresponding control value. Analysis of covariance was conducted to test for statistic significance (t : t ratio; p : p value). C)

[³H]-dCy uptake assay: the [³H] labeled dCy (0.5 μCi/ml, 0.02 nmol/ml) was added into cell culture medium. The following procedure is the same as above.

Figure 5. Suppression of [³H]-Gem efflux by using azide

A) [³H]-Gem efflux assay: The cells were incubated with 85, 175, 350 and 700 nM of [³H]-Gem for 24 hours, washed and then changed with fresh medium for 1 hour. 500 μl from 2ml medium was counted to evaluate [³H]-Gem in efflux. B) 2×10⁵ KBwt cells were pre-treated with different dosages of sodium azide for 3 hours. The cells were incubated with [³H]-Gem (0.5 μCi/ml, 0.02 nmol/ml) for 3 hour, then washed and re-suspended with medium containing 0.02 nmol/ml unlabeled Gem for 30, 60, 120 and 240 minutes. 100 μl from 1ml medium was counted; and results were normalized by corresponding controls. The statistical significance was analyzed by using covariance analysis. C) [³H]-dCy efflux assay: the [³H] labeled dCy

(0.5 $\mu\text{Ci/ml}$, 0.02 nmol/ml) was added into cell culture medium of KBGem. The following procedure is the same as above.

Figure 6. Increase of CCOX and disruption of Gem incorporation into DNA in KBGem

Gem is phosphorylated by dCK, dCMPK and NDPK, and then converted to the final formation, dFdCTP, to incorporate in DNA chain and cause DNA chain termination. Increase of CCOX activity and ATP synthase could inhibit dCMPK activity by increasing production of ATP, which reduces Gem metabolism into dFdCTP. Meanwhile, ATP activates the RR activity by binding to the activity site of hRRM1 subunit. Up-regulation of RR activity may expand the dCTP pool. Thus, synergetic effects of dCTP pool expansion and dFdCTP decrease may prevent Gem from incorporating into DNA and cause Gem resistance in KBGem.

Table 1
Characterization of drug resistant clones and parental cell

	KBwt	KBGem	KBHURs
Relative amounts of mRNA ^a			
hRRM1	1.0	1.2	1.5
hRRM2*	1.0	29.3	32.0
P53R2	1.0	0.9	1.0
Relative amounts of protein ^b			
hRRM1	1.0	1.0	1.1
hRRM2 [#]	1.0	9.0	10.0
P53R2	1.0	1.0	1.0
Relative RR activity ^c	1.0	2.3	6.7
dCTP pool(pmol/1,000,000 cell) ^d	0.90±0.58	1.80±0.95	13.4±6.73

^a Determined from phosphorimaging measurements of signal hybridizing with corresponding probe with RNA extracted from KBwt and KBGem clones. Data was normalized with a signal value of GAPDH.

* mRNA of hRRM2 increases significantly in KBGem and KBHURs (grouped t-test, n=3, $p<0.01$).

^b Western blot was employed to evaluate the protein level of KBwt and KBGem clones. The results were normalized with a signal value of α -tubulin.

[#] Protein levels of hRRM2 increase significantly in KBGem and KBHURs (grouped t-test, n=3, $p<0.01$).

^c & ^d RR activity and dCTP pool assay were described in our previous paper [44].

Table 2

Identification of fragments of RFDD-PCR

Fragments	BLAST search results ^a			
	blastn ^b		blastx ^c	
	Gene	Identities	Protein	Identities
E12G5-5	Mitochondrion	99 %	CCOX III	97 %
E32G5	Poly(A) Binding Protein	100 %	Poly(A) Binding Protein	97 %
E33G5	Mitochondrion	96 %	NS ^d	
E33G5L	Mitochondrion	99 %	CCOX III	89 %
E33G5S	NS ^d	--	NS ^d	--
E34G5L	Mitochondrion	100 %	CCOX III	95 %
E48G5	1-Thymosin beta 10	92 %	NS ^d	--
	2- Migration-inducing protein 12	92 %		
E51G5	Mitochondrion	94 %	NADH dehydrogenase subunit 1	84 %
E9G5-10	TNF receptor-associated factor 4 isoform 1	98 %	1-TNF receptor- associated factor 4 isoform 1	100 %
			2-Cystein rich domain associated to RING and TRAF protein	100 %

^aBLAST: basic local alignment search tool (<http://www.ncbi.nlm.nih.gov/BLAST/>)

^bNucleotide-nucleotide BLAST

^cTranslated query vs. protein database, Nucleotide-protein BLAST

^dNS: no significance found

Table 3

Expression profile of Respiration complexes' genes

Systematic	KB		KBGem [*]		KBHURs [#]		Gene	Genbank
	Raw	Normalized	Raw	Normalized	Raw	Normalized		
Complex I, NADH Dehydrogenase (Ubiquinone)								
40546_s_at	1740.7	1.53	2565	0.44	1468.6	0.78	NDUFA2	AF047185
32752_at	6893.2	2.39	15895.7	0.51	4690.1	0.63	NDUFA7	W72440
32774_at	1413.7	1.68	2298.1	2.07	1443.5	0.95	NDUFB8	AI541050
36169_at	24882.6	1.10	26412.8	0.78	23343.6	0.87	NDUFA1	N47307
38060_at	8974	2.45	21215.9	2.34	7122.8	0.74	NDUFS5	AI541336
38695_at	1262.3	1.28	1559.7	0.86	1607.4	1.18	NDUFS4	AA203303
32738_at	1253.3	0.86	1039.5	2.15	1029.3	0.76	NDUFS2	AF050640
36205_at	642.9	2.15	1333.4	1.03	839.9	1.21	NDUFA9	L04490
Complex II, Succinate Dehydrogenase								
34826_at	3995.4	0.98	3796.1	0.94	5594.1	1.30	SDHA	L21936
35751_at	832.6	1.77	1421.5	0.44	900	1.00	SDHB	U17886
ComplexIII, Ubiquinol-Cytochrome C Reductase								
40854_at	2185.4	0.44	921.8	0.44	1544.3	0.66	UQCRC2	J04973
39427_at	6601.8	0.51	3222.3	0.51	6534.6	0.92	UQCRB	T79616
34400_at	17961.1	2.07	35961.6	2.07	14174.7	0.73	QP-C	AI540957
36104_at	4401.2	0.78	3315.5	0.78	3814.5	0.80	UQCRH	AA526497
38451_at	1403.1	2.34	3167.3	2.34	1119.2	0.74	UQCR	T58471
Complex IV, Cytochrome C Oxidase								
40427_at	1141.9	0.94	1033.6	0.94	1095.2	0.89	CCOX17	AA149486
41223_at	971.5	0.63	592.3	0.63	720.9	0.69	CCOX5A	M22760
39443_s_at	3051.7	2.31	6813	2.31	2091.3	0.64	CCOX5B	M19961
41206_r_at	2414.2	2.70	6303.9	2.70	1710.2	0.66	CCOX6A1	AI540925
36165_at	5659.5	0.81	4452.5	0.81	4633	0.76	CCOX6C	W51774
41760_at	2413.6	3.13	7305.7	3.13	2102.6	0.81	CCOX7A2	AA978033
36687_at	8131.6	1.25	9844	1.25	11017.2	1.26	CCOX7B	N50520
34381_at	8714.4	0.89	7479.8	0.89	9982.4	1.06	CCOX7C	AI708889
38080_at	15853.4	2.06	31564.1	2.06	9329.8	0.55	CCOX8	AI525665
38660_at	771.4	1.40	1045.6	1.40	695.6	0.84	CCOX6A2	F27891
40872_at	688	6.61	4391	6.61	823.5	1.11	CCOX6B	T57872
34723_at	340.8	1.03	338.6	1.03	259.2	0.70	CCOX11	U79270
Complex V, ATP synthase								
41357_at	3148.4	1.26	3838.3	1.26	5571.3	1.64	ATP5B	W27997
40115_at	12487.2	1.81	21879.4	1.81	3582.6	0.27	ATP5C1	D16562
37992_s_at	3008.9	1.38	3994.9	1.38	1305.1	0.40	ATP5D	AI436567
36107_at	1848.8	1.19	2120	1.19	1369.9	0.69	ATP5J	AA845575
37029_at	2344.2	1.10	2480.7	1.10	2489.2	0.98	ATP5O	X83218
34811_at	2370.8	1.45	3315.1	1.45	1659.1	0.65	ATP5G3	U09813
35760_at	1336.5	1.08	1387.6	1.08	2523.7	1.75	ATP5H	AF087135
38751_i_at	108199.1	1.28	133973.7	1.28	107770.2	0.92	ATP5I	AA426364
40134_at	1258.8	5.06	6149.1	5.06	1233.9	0.91	ATP5J2	AF047436

* Paired t-test, $p=0.004$, KBGem compared with parental KB cell.

Paired t-test, $p=0.076$, KBHURs compared with parental KB cell.